MediWound Ltd., a global leader in enzymatic therapeutics for tissue repair, has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel. The expansion marks a significant step toward increasing production capacity for its burn treatment product, NexoBrid®, by approximately sixfold. The facility is expected to be fully operational by the end of 2025, positioning MediWound to meet growing global demand and ensure a reliable supply of NexoBrid in over 40 approved markets, pending regulatory review.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567190-en) on November 03, 2025, and is solely responsible for the information contained therein.